Rankings
▼
Calendar
TSHA Q3 2023 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena
TSHA
Taysha Gene Therapies, Inc.
$1B
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
Gross Profit
$4M
93.0% margin
Operating Income
-$16M
-329.4% margin
Net Income
-$117M
-2467.1% margin
EPS (Diluted)
$-0.93
QoQ Revenue Growth
+98.2%
Cash Flow
Operating Cash Flow
-$18M
Free Cash Flow
-$21M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$196M
Total Liabilities
$245M
Stockholders' Equity
-$49M
Cash & Equivalents
$164M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$5M
$0
—
Gross Profit
$4M
$0
—
Operating Income
-$16M
-$25M
+38.6%
Net Income
-$117M
-$27M
-341.4%
← FY 2023
All Quarters
Q4 2023 →